TriLink BioTechnologies collaborates with Johns Hopkins University to establish a new RNA Innovation Center
13 Maggio 2024 - 2:00PM
Business Wire
The collaborative center will help to lower
barriers to RNA innovation and discovery
TriLink BioTechnologies (TriLink®), a Maravai™ LifeSciences
company (NASDAQ: MRVI) and global provider of life science reagents
and services, is collaborating with the Johns Hopkins University to
accelerate transformational research in RNA therapeutics and
discovery. A new center within the Johns Hopkins Whiting School of
Engineering will accelerate research and therapeutic development,
leveraging TriLink’s leading RNA synthesis technology.
TriLink’s investment includes direct funding for the center and
access to TriLink’s proprietary in vitro transcription technology,
CleanScript™, which will enable Hopkins researchers to advance mRNA
development. Additionally, TriLink will provide technical expertise
and access to other critical discovery and manufacturing supplies,
further lowering the barriers to discovery and application.
“The collaboration with Johns Hopkins reinforces our commitment
to advancing nucleic acid-based therapies,” commented Drew Burch,
President, Nucleic Acid Products, Maravai LifeSciences. “Our
participation in this center of excellence allows TriLink to share
its deep knowledge and expertise in nucleic acid production,
helping to enable these researchers at Hopkins with the tools they
need to develop advanced therapies to treat patients."
According to Ed Schlesinger, dean of the Whiting School of
Engineering, the aspiration for this center is the transformation
of human health through the development of breakthroughs in RNA
applications. Schlesinger adds that the availability of
cutting-edge discovery tools will enable Johns Hopkins to grow its
RNA research community and increase the cycle of innovation on
campus.
Jeff Coller, Bloomberg Distinguished Professor of RNA Biology
and Therapeutics and a leader in messenger RNA stability and
translation will serve as the inaugural director of the center,
which will be anchored in the Institute of NanoBioTechnology (INBT)
and open this spring. The center will bring together Johns Hopkins
experts in RNA biology, genetic medicine, drug delivery, and
biotechnology under one roof, serving as a training center for the
next generation of RNA investigators and as a one-university nexus
for RNA researchers across the various schools.
About TriLink BioTechnologies
TriLink BioTechnologies, a Maravai LifeSciences company, is a
global leader in nucleic acid and mRNA solutions. TriLink delivers
unrivaled chemical and biological experience, CDMO services, and
high-quality readymade and custom materials, including its patented
CleanCap® mRNA capping technology. Pharmaceutical leaders, biotech
disruptors, and world governments depend on TriLink to meet their
greatest challenges, from delivering the COVID-19 vaccine at warp
speed, to empowering innovative treatments in oncology, infectious
diseases, cardiology, and neurological disorders, to enabling
future pandemic response plans.
For more information, visit trilinkbiotech.com
About Maravai LifeSciences
Maravai is a leading life sciences company providing critical
products to enable the development of drug therapies, diagnostics,
and novel vaccines. Maravai’s companies are leaders in providing
products and services in the fields of nucleic acid synthesis and
biologics safety testing to many of the world’s leading
biopharmaceutical, vaccine, diagnostics, and cell and gene therapy
companies.
For more information about Maravai LifeSciences, visit
maravai.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240513577547/en/
Media Contact: Liz Robinson of CG Life TriLink BioTechnologies
+1 312-997-2436 lrobinson@cglife.com
Investor Contact: Deb Hart Maravai LifeSciences + 1 858-988-5917
ir@maravai.com
Grafico Azioni Maravai LifeSciences (NASDAQ:MRVI)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Maravai LifeSciences (NASDAQ:MRVI)
Storico
Da Dic 2023 a Dic 2024